Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 1 Squamous Intraepithelial Lesions 1 Skin Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Mycosis Fungoides 1 Melanoma 1 Leukoplakia 1 Leukokeratosis, Hereditary Mucosal 1 HIV Infections 1 Glioma 1 Glioblastoma 1 Ependymoma 1 Colorectal Neoplasms 1 Carcinoma, Basal Cell 1

Interventions

Temozolomide 42 Magnetic Resonance Spectroscopy 41 Radiotherapy 22 Specimen Handling 18 Biopsy 13 X-Rays 10 Radiation 10 trametinib 8 Bevacizumab 8 Nivolumab 7 Blood Specimen Collection 7 olaparib 6 fluorodopa F 18 6 dabrafenib 6 Radiotherapy, Intensity-Modulated 6 Phantoms, Imaging 6 Nuclear Medicine Department, Hospital 6 Lomustine 6 pembrolizumab 5 abemaciclib 5 Standard of Care 5 vorasidenib 4 ulixertinib 4 larotrectinib 4 ivosidenib 4 erdafitinib 4 Surgical Procedures, Operative 4 Dianhydrogalactitol 4 Cyclophosphamide 4 Aminolevulinic Acid 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Glioma × Imiquimod × 1 year × Clear all

NCT04808245 2025-09-22

INTERCEPT-H3

German Cancer Research Center

Phase 1 Active not recruiting

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡